Yeo Woon Koo (KBSI, UST)

Kun Cho (KBSI, UST)

Yeo Woon Koo (KBSI, UST)

Duck-Hyun Kim (KBSI)

Kun Cho (KBSI, UST)

Doxorubicin (DOX) is a widely used anticancer agent that inhibits DNA synthesis and replication, thereby arresting the cell cycle and inducing apoptosis in rapidly dividing cancer cells. Despite its effectiveness, long-term use of DOX causes severe side effects. To mitigate these, liposomal doxorubicin, the first FDA-approved nanostructured drug, was developed. However, its clinical efficacy remains debated.

This study aims to optimize the quantitative analysis method for liposomal doxorubicin using Triple Quadrupole Mass Spectrometry, a mass analysis instrument. Mouse serum samples were spiked with DOX at a concentration of 10 ppm. Sample pre-treatment recovery rates were compared using Solid-Phase Extraction (SPE) and Centrifugation methods.

SPE showed higher recovery rates at lower concentrations, while recovery rates using centrifugation decreased at higher DOX concentrations. Based on these findings, centrifugation was selected as the pre-treatment method for mouse serum samples. Future experiments will compare recovery rates at higher concentrations (2-20 ppm).

While a definitive pre-treatment method has not yet been established, centrifugation showed promise for DOX recovery in mouse serum samples. Ongoing optimization will continue until exosome incorporation with mouse plasma and DOX is achieved to enhance targeted delivery and reduce toxicity.